NO20065918L - Tetrahydroioskinolonderivater, fremstilling derav og anvendelse som terapeutisk middel - Google Patents
Tetrahydroioskinolonderivater, fremstilling derav og anvendelse som terapeutisk middelInfo
- Publication number
- NO20065918L NO20065918L NO20065918A NO20065918A NO20065918L NO 20065918 L NO20065918 L NO 20065918L NO 20065918 A NO20065918 A NO 20065918A NO 20065918 A NO20065918 A NO 20065918A NO 20065918 L NO20065918 L NO 20065918L
- Authority
- NO
- Norway
- Prior art keywords
- group
- alkylidene
- alkyl
- hydrogen atom
- optionally substituted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 125000001118 alkylidene group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 abstract 1
- 125000002070 alkenylidene group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Det er beskrevet en forbindelse av formel (I), hvori n kan bety en verdi mellom 1 og 6; -(C)n- betyr en C1-6 alkyliden gruppe, eventuelt substituert med mellom 1 og 4 substitu-enter; RI betyr et hydrogenatom eller en C1-6 alkyl gruppe; R2 betyr et hydrogenatom, en C1-6 alkyl eller C3.6 sykloalkyl gruppe, eventuelt substituert med mellom 1 og 4 substituenter; og B betyr NR3R4, idet R3 og R4 uavhengig av hverandre betyr en C1-6 alkyl gruppe eller et hydrogenatom, eller betyr sammen en Q.6 alkyliden gruppe, en C2-8 alkenyliden gruppe, en C 1.3 alkyliden-O-Ci-3 alkyliden gruppe eller en C 1.3 alkyliden-N(R5)-Ci-3 alkyliden gruppe, hvor R5 betyr et hydrogenatom, eller en C1-3 alkyl eller C1-6 alkylkarbonylgruppe, idet nevnte C1.3 alkyl og C1-6 alkylkarbonyl grupper er sub stituerbare, eller en aminosyklus som er forbundet via et karbonatom til gruppen -NR1-(C)n-, så som aziridin, azetidin, pyrrolidin, piperidin eller morfolin, idet gruppene R3, R4, aminosyklusen og nitrogenatomet eventuelt er substituerte. Oppfinnelsen kan anvendes innenfor terapi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0405607A FR2870846B1 (fr) | 2004-05-25 | 2004-05-25 | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| PCT/FR2005/001279 WO2005118547A1 (fr) | 2004-05-25 | 2005-05-24 | Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20065918L true NO20065918L (no) | 2006-12-19 |
| NO338104B1 NO338104B1 (no) | 2016-08-01 |
Family
ID=34944870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20065918A NO338104B1 (no) | 2004-05-25 | 2006-12-19 | Tetrahydroisoquinolin-sulfonamid-derivater, farmasøytiske preparater inneholdende slike og anvendelse derav som terapeutisk middel |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US7833999B2 (no) |
| EP (1) | EP1753725B1 (no) |
| JP (1) | JP4861979B2 (no) |
| KR (1) | KR101176675B1 (no) |
| CN (1) | CN1956962B (no) |
| AR (1) | AR050250A1 (no) |
| AU (1) | AU2005250197B2 (no) |
| BR (1) | BRPI0511581A (no) |
| CA (1) | CA2565293C (no) |
| CR (1) | CR8735A (no) |
| CY (1) | CY1114240T1 (no) |
| DK (1) | DK1753725T3 (no) |
| DO (1) | DOP2005000103A (no) |
| EA (1) | EA010234B1 (no) |
| EC (1) | ECSP067020A (no) |
| ES (1) | ES2407140T3 (no) |
| FR (1) | FR2870846B1 (no) |
| GT (1) | GT200500126A (no) |
| HN (1) | HN2005000239A (no) |
| HR (1) | HRP20130431T1 (no) |
| IL (1) | IL179021A (no) |
| JO (1) | JO2877B1 (no) |
| MA (1) | MA28720B1 (no) |
| MX (1) | MXPA06013629A (no) |
| MY (1) | MY148980A (no) |
| NI (1) | NI200600279A (no) |
| NO (1) | NO338104B1 (no) |
| NZ (1) | NZ551509A (no) |
| PA (1) | PA8634501A1 (no) |
| PE (1) | PE20060273A1 (no) |
| PL (1) | PL1753725T3 (no) |
| PT (1) | PT1753725E (no) |
| SI (1) | SI1753725T1 (no) |
| SV (1) | SV2006002126A (no) |
| TN (1) | TNSN06356A1 (no) |
| TW (1) | TWI360540B (no) |
| UA (1) | UA84771C2 (no) |
| UY (1) | UY28917A1 (no) |
| WO (1) | WO2005118547A1 (no) |
| ZA (1) | ZA200609820B (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| EP1790646A1 (fr) * | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
| BRPI0820432B8 (pt) | 2007-11-13 | 2021-05-25 | Taisho Pharmaceutical Co Ltd | derivados de fenilpirazol apresentando atividade de antagonista de receptor de histamina h3 e um agente profilático ou terapeutico compreendendo tais derivados |
| TW201039822A (en) | 2009-02-06 | 2010-11-16 | Taisho Pharmaceutical Co Ltd | Dihydroquinolinone derivatives |
| AU2010264422B2 (en) | 2009-06-26 | 2014-12-18 | Sanofi | Novel fumarate salts of a histamine H3 receptor antagonist |
| AR080374A1 (es) * | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida |
| EP2789608A4 (en) | 2011-12-08 | 2015-07-01 | Taisho Pharmaceutical Co Ltd | PHENYLPYRROLDERIVAT |
| TW201343636A (zh) | 2011-12-27 | 2013-11-01 | 大正製藥股份有限公司 | 苯基三唑衍生物 |
| EP2647377A1 (en) * | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
| CN105764510A (zh) * | 2013-09-09 | 2016-07-13 | 赛诺菲 | H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途 |
| CN110642854A (zh) * | 2019-11-20 | 2020-01-03 | 成都克莱蒙医药科技有限公司 | 一种稠环化合物的多晶型、其组合物、制备方法及其应用 |
| WO2022113008A1 (en) | 2020-11-27 | 2022-06-02 | Richter Gedeon Nyrt. | Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0702671A4 (en) * | 1993-06-09 | 1996-06-19 | Smithkline Beecham Corp | BICYCLIC FIBRINOGEN ANTAGONISTS |
| GB9508622D0 (en) * | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
| RU2182904C2 (ru) * | 1996-02-09 | 2002-05-27 | Джеймс Блэк Фаундейшн Лимитед | Сульфонамиды и способы их получения |
| PL343424A1 (en) | 1998-04-10 | 2001-08-13 | Japan Tobacco Inc | Amidine compounds |
| JP2003500382A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子の阻害剤 |
| CA2432578C (en) | 2001-01-02 | 2008-04-01 | F. Hoffmann-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| JP2004532834A (ja) * | 2001-03-23 | 2004-10-28 | イーライ・リリー・アンド・カンパニー | ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用 |
| JP2003192660A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
| WO2003055848A2 (en) * | 2001-12-26 | 2003-07-10 | Bayer Healthcare Ag | Urea derivatives as vr1- antagonists |
| KR100984655B1 (ko) | 2002-03-08 | 2010-10-01 | 사카타 인쿠스 가부시키가이샤 | 처리안료, 그 용도 및 안료처리용 화합물 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| EA011095B1 (ru) * | 2002-08-29 | 2008-12-30 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний |
| EP1680411A2 (en) | 2003-10-08 | 2006-07-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| JPWO2005040135A1 (ja) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
| FR2870846B1 (fr) * | 2004-05-25 | 2006-08-04 | Sanofi Synthelabo | Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique |
| EP1630158A1 (en) | 2004-08-18 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
| ES2257168B1 (es) | 2004-08-18 | 2007-06-01 | Laboratorios Del Dr Esteve, S.A. | Ligandos del receptor 5-ht7. |
| US20080261999A1 (en) | 2005-03-04 | 2008-10-23 | Fionna Mitchell Martin | Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists |
| EP1790646A1 (fr) * | 2005-11-24 | 2007-05-30 | Sanofi-Aventis | Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3. |
-
2004
- 2004-05-25 FR FR0405607A patent/FR2870846B1/fr not_active Expired - Lifetime
-
2005
- 2005-05-23 AR ARP050102107A patent/AR050250A1/es not_active Application Discontinuation
- 2005-05-23 PE PE2005000566A patent/PE20060273A1/es not_active Application Discontinuation
- 2005-05-23 JO JO200571A patent/JO2877B1/en active
- 2005-05-23 HN HN2005000239A patent/HN2005000239A/es unknown
- 2005-05-24 GT GT200500126A patent/GT200500126A/es unknown
- 2005-05-24 EP EP05772938A patent/EP1753725B1/fr not_active Expired - Lifetime
- 2005-05-24 AU AU2005250197A patent/AU2005250197B2/en not_active Ceased
- 2005-05-24 PL PL05772938T patent/PL1753725T3/pl unknown
- 2005-05-24 HR HRP20130431TT patent/HRP20130431T1/hr unknown
- 2005-05-24 CN CN200580016856.7A patent/CN1956962B/zh not_active Expired - Lifetime
- 2005-05-24 JP JP2007514007A patent/JP4861979B2/ja not_active Expired - Lifetime
- 2005-05-24 NZ NZ551509A patent/NZ551509A/en not_active IP Right Cessation
- 2005-05-24 ZA ZA200609820A patent/ZA200609820B/xx unknown
- 2005-05-24 SI SI200531708T patent/SI1753725T1/sl unknown
- 2005-05-24 WO PCT/FR2005/001279 patent/WO2005118547A1/fr not_active Ceased
- 2005-05-24 ES ES05772938T patent/ES2407140T3/es not_active Expired - Lifetime
- 2005-05-24 UY UY28917A patent/UY28917A1/es not_active Application Discontinuation
- 2005-05-24 CA CA2565293A patent/CA2565293C/fr not_active Expired - Fee Related
- 2005-05-24 EA EA200602176A patent/EA010234B1/ru not_active IP Right Cessation
- 2005-05-24 PT PT57729386T patent/PT1753725E/pt unknown
- 2005-05-24 TW TW094116907A patent/TWI360540B/zh not_active IP Right Cessation
- 2005-05-24 BR BRPI0511581-7A patent/BRPI0511581A/pt not_active Application Discontinuation
- 2005-05-24 KR KR1020067024780A patent/KR101176675B1/ko not_active Expired - Fee Related
- 2005-05-24 MX MXPA06013629A patent/MXPA06013629A/es active IP Right Grant
- 2005-05-24 DK DK05772938.6T patent/DK1753725T3/da active
- 2005-05-24 SV SV2005002126A patent/SV2006002126A/es active IP Right Grant
- 2005-05-24 UA UAA200613640A patent/UA84771C2/uk unknown
- 2005-05-24 MY MYPI20052337A patent/MY148980A/en unknown
- 2005-05-25 DO DO2005000103A patent/DOP2005000103A/es unknown
- 2005-05-25 PA PA20058634501A patent/PA8634501A1/es unknown
-
2006
- 2006-11-02 IL IL179021A patent/IL179021A/en not_active IP Right Cessation
- 2006-11-03 TN TNP2006000356A patent/TNSN06356A1/en unknown
- 2006-11-07 CR CR8735A patent/CR8735A/es unknown
- 2006-11-15 US US11/559,929 patent/US7833999B2/en active Active
- 2006-11-22 EC EC2006007020A patent/ECSP067020A/es unknown
- 2006-11-23 NI NI200600279A patent/NI200600279A/es unknown
- 2006-12-04 MA MA29510A patent/MA28720B1/fr unknown
- 2006-12-19 NO NO20065918A patent/NO338104B1/no not_active IP Right Cessation
-
2010
- 2010-10-08 US US12/901,063 patent/US8273733B2/en not_active Expired - Lifetime
-
2012
- 2012-08-24 US US13/593,832 patent/US8524700B2/en not_active Expired - Lifetime
-
2013
- 2013-05-24 CY CY20131100411T patent/CY1114240T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20065918L (no) | Tetrahydroioskinolonderivater, fremstilling derav og anvendelse som terapeutisk middel | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| NO20073743L (no) | Forbindelser med Kv4 ionekanal aktivitet | |
| NO20062292L (no) | Fremgangsmate for behandling av transplantasjonsavstoting | |
| NO20091394L (no) | Pyridin-4-yl-derivater som immunmodulerende midler | |
| MX2010003445A (es) | Derivados de nicotinamida, su preparacion y su uso terapeutico. | |
| MX2009002919A (es) | Derivados de azetidina y azetidona utiles en el tratamiento del dolor y trastornos del metabolismo de los lipidos. | |
| NO20064669L (no) | Dipeptidylpeptidaseinhibitorer | |
| MXPA05010433A (es) | Derivados de pirrolidina y procedimiento para prepararlos. | |
| NO20064077L (no) | Kemokinreseptorantagonister | |
| NO20070445L (no) | Pyrimidinderivater. | |
| NO20072806L (no) | Aryloksy-substituerte benzimidazolderivater | |
| NO20080394L (no) | N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav | |
| MX2009012380A (es) | Compuestos de heteroarilamida pirimidona. | |
| NO984761L (no) | Aminoisokinoliner og aminotienopyridinderivater og deres anvendelse som antiinflammatoriske midler | |
| MX2010008360A (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos. | |
| WO2008139845A1 (ja) | 新規アミド誘導体 | |
| MX2009003051A (es) | Derivados de quinolinona. | |
| TW200420292A (en) | Benzofuran derivative | |
| NO20082226L (no) | 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav | |
| TW200504059A (en) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | |
| NO20053483L (no) | 4-Anilinokinazolinderivater for behandling av unormal cellevekst | |
| NO20065873L (no) | 3-(4-(2-dihydroisoksazol-3-ylpyridin-5-yl)fenyl)-5-triazol-1-ylmetyloksoazolidin-2-on derivater som MAO inhibitorer i behandlingen av bakterielle infeksjoner | |
| NO20064821L (no) | Nye pyrrolidin-3,4-Dikarboksamidderivater | |
| TW200503699A (en) | Acylaminothiazole derivatives, their preparation and their therapeutic use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |